Literature DB >> 1430883

Economic considerations in breast cancer screening of older women.

M L Brown1.   

Abstract

The incidence of breast cancer increases with age, tending to result in more favorable cost-effectiveness outcomes with more advanced age of the screened population. On the other hand, the decreased remaining life expectancy of older women can be expected to reduce the cost effectiveness of screening. To assess these competing factors, the cost effectiveness of a long-term breast cancer screening program was evaluated using a computerized simulation model. The cost per life year saved decreased when the 65-69 year age group was added to a program screening women aged 50-64. For older age groups, however, cost effectiveness became relatively less favorable. The cost per life year saved of screening the 80-84 year age group was 55% higher than for the 65-69 group.

Entities:  

Mesh:

Year:  1992        PMID: 1430883

Source DB:  PubMed          Journal:  J Gerontol        ISSN: 0022-1422


  4 in total

1.  Clinical and economic arguments favour extension to upper age limit for breast screening.

Authors:  D J Torgerson; T Gosden
Journal:  BMJ       Date:  1998-06-13

Review 2.  Cost-effectiveness of breast cancer screening: preliminary results of a systematic review of the literature.

Authors:  M L Brown; L Fintor
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

3.  Neglected aspects of false positive findings of mammography in breast cancer screening: analysis of false positive cases from the Stockholm trial.

Authors:  E Lidbrink; J Elfving; J Frisell; E Jonsson
Journal:  BMJ       Date:  1996-02-03

4.  Toward optimal screening strategies for older women. Costs, benefits, and harms of breast cancer screening by age, biology, and health status.

Authors:  Jeanne S Mandelblatt; Clyde B Schechter; K Robin Yabroff; William Lawrence; James Dignam; Martine Extermann; Sarah Fox; Gretchen Orosz; Rebecca Silliman; Jennifer Cullen; Lodovico Balducci
Journal:  J Gen Intern Med       Date:  2005-06       Impact factor: 5.128

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.